Search results
Results From The WOW.Com Content Network
26361 Ensembl ENSG00000198049 ENSMUSG00000026432 UniProt P47901 Q9WU02 RefSeq (mRNA) NM_000707 NM_011924 RefSeq (protein) NP_000698 NP_036054 Location (UCSC) Chr 1: 206.11 – 206.12 Mb Chr 1: 131.53 – 131.54 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Vasopressin V1b receptor (V1BR) also known as vasopressin 3 receptor (VPR3) or antidiuretic hormone receptor 1B is a protein ...
Natriuretic peptides and their receptors have many different effects on the body, such as controlling blood pressure and helping bones grow. Each peptide has its own unique effects and interacts with specific receptors. Scientists have observed these effects by studying mice with specific natriuretic peptides or receptors removed. [3]
The human V 3 receptor (V 3 R, previously known as V 1B R) is a G-protein-coupled pituitary receptor that, because of its scarcity, was only recently characterized. [1] The 424-amino-acid sequence of the V 3 R has homologies of 45%, 39%, and 45% with the V 1 R, V 2 R and oxytocin receptor (OTR), respectively.
The "vaptan" drugs act by directly blocking the action of vasopressin at its receptors (V 1A, V 1B and V 2).These receptors have a variety of functions, with the V 1A and V 2 receptors are expressed peripherally and involved in the modulation of blood pressure and kidney function respectively, while the V 1A and V 1B receptors are expressed in the central nervous system.
Vasopressin agonists are used therapeutically in various conditions, and its long-acting synthetic analogue desmopressin is used in conditions featuring low vasopressin secretion, as well as for control of bleeding (in some forms of von Willebrand disease and in mild haemophilia A) and in extreme cases of bedwetting by children.
Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). The compound was discovered by Astellas and marked in 2006. The drug is now marketed by Cumberland Pharmaceuticals, Inc.
Central diabetes insipidus, recently renamed arginine vasopressin deficiency (AVP-D), [1] is a form of diabetes insipidus that is due to a lack of vasopressin (ADH) production in the brain. Vasopressin acts to increase the volume of blood (intravascularly), and decrease the volume of urine produced.
Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V 2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH).